PMC:7443692 / 1038-1320 JSONTXT

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T8","span":{"begin":19,"end":174},"obj":"Sentence"},{"id":"T9","span":{"begin":176,"end":194},"obj":"Sentence"},{"id":"T10","span":{"begin":196,"end":206},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"tor glycosylation. Taken together, these data can facilitate immunogen design to achieve antibody neutralization and inform therapeutic strategies to inhibit viral infection.\n\nGraphical Abstract\n\nHighlights\n• Site-specific N-linked microheterogeneity is defined at 22 sites of SARS"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T3","span":{"begin":158,"end":173},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"}],"text":"tor glycosylation. Taken together, these data can facilitate immunogen design to achieve antibody neutralization and inform therapeutic strategies to inhibit viral infection.\n\nGraphical Abstract\n\nHighlights\n• Site-specific N-linked microheterogeneity is defined at 22 sites of SARS"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T6","span":{"begin":164,"end":173},"obj":"http://purl.obolibrary.org/obo/IDO_0000586"},{"id":"T7","span":{"begin":210,"end":214},"obj":"http://purl.obolibrary.org/obo/BFO_0000029"},{"id":"T8","span":{"begin":269,"end":274},"obj":"http://purl.obolibrary.org/obo/BFO_0000029"}],"text":"tor glycosylation. Taken together, these data can facilitate immunogen design to achieve antibody neutralization and inform therapeutic strategies to inhibit viral infection.\n\nGraphical Abstract\n\nHighlights\n• Site-specific N-linked microheterogeneity is defined at 22 sites of SARS"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T8","span":{"begin":89,"end":97},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"tor glycosylation. Taken together, these data can facilitate immunogen design to achieve antibody neutralization and inform therapeutic strategies to inhibit viral infection.\n\nGraphical Abstract\n\nHighlights\n• Site-specific N-linked microheterogeneity is defined at 22 sites of SARS"}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T3","span":{"begin":4,"end":17},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T4","span":{"begin":158,"end":173},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"tor glycosylation. Taken together, these data can facilitate immunogen design to achieve antibody neutralization and inform therapeutic strategies to inhibit viral infection.\n\nGraphical Abstract\n\nHighlights\n• Site-specific N-linked microheterogeneity is defined at 22 sites of SARS"}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T3","span":{"begin":4,"end":17},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T4","span":{"begin":158,"end":173},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"tor glycosylation. Taken together, these data can facilitate immunogen design to achieve antibody neutralization and inform therapeutic strategies to inhibit viral infection.\n\nGraphical Abstract\n\nHighlights\n• Site-specific N-linked microheterogeneity is defined at 22 sites of SARS"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T23","span":{"begin":61,"end":70},"obj":"CHEBI:60816;CHEBI:60816"},{"id":"T24","span":{"begin":89,"end":97},"obj":"GO:0042571"},{"id":"T25","span":{"begin":158,"end":163},"obj":"NCBITaxon:10239"}],"text":"tor glycosylation. Taken together, these data can facilitate immunogen design to achieve antibody neutralization and inform therapeutic strategies to inhibit viral infection.\n\nGraphical Abstract\n\nHighlights\n• Site-specific N-linked microheterogeneity is defined at 22 sites of SARS"}